HONG KONG DRUG LICENSING
Hong Kong Drug Licence FAQs
Search 500 Hong Kong drug licence FAQs on applications, personnel, premises, quality systems, ongoing regulation, renewals and acquisitions.
Information status: The original FAQ material dates from 2025 and is provided for topic-based reference; it does not represent an individual verification of all 500 FAQs against current rules. For application, fee, renewal, change, product or prescription requirements, please refer to the current official forms and guidance.
Official information from the Drug Office Official information from the Chinese Medicines Board
找到 500 条结果，第 24／25 页。每页显示 20 条；无需启用 JavaScript。
Q461 · 香港药品注册申请流程的主要步骤有哪些？独立链接
The medicine registration process in Hong Kong mainly comprises the following steps: first, prepare a complete application, including the medicine package insert and quality and safety information; next, submit the registration application to the Drug Office, Department of Health, and pay the relevant fees; the Drug Office will then review the information and may conduct an on-site inspection; finally, if the requirements of the Pharmacy and Poisons Ordinance (Cap.138) are met, a pharmaceutical product registration number (such as HK-XXXXX) will be issued, allowing the medicine to be sold in Hong Kong. The process usually takes several months. Applicants should ensure that the information is accurate and complete to avoid delays.
Q462 · 香港药牌（HK-XXXXX）编号是如何分配和管理的？独立链接
The Drug Office, Department of Health, allocates Hong Kong pharmaceutical licence numbers centrally. Each approved registered medicine receives a unique number to identify it and regulate its sale on the market. The “HK-” prefix denotes Hong Kong, and the following digits are generated in registration date order. The licence number must be clearly displayed on the medicine packaging and package insert to enable tracking and verification. This numbering system helps regulators monitor the distribution and safety of medicines.
Q463 · 香港药品注册与内地药品注册有哪些核心差异？独立链接
Hong Kong medicine registration focuses on medicine quality, safety and labelling compliance. The process is relatively straightforward and does not require clinical trial data to have been generated locally. By contrast, registration of medicines in Mainland China under the Measures for the Administration of Drug Registration is more complex, requiring rigorous clinical trials and consistency evaluations, with longer approval times. Hong Kong focuses on regulation under the Pharmacy and Poisons Ordinance (Cap.138), with an emphasis on post-market oversight, whereas Mainland China has strict pre-market approval by the National Medical Products Administration. The requirements for registration information and approval procedures differ significantly between the two jurisdictions, so businesses need to prepare accordingly.
Q464 · 申请香港药牌时，是否需要提交临床试验数据？独立链接
Hong Kong medicine registration does not usually require applicants to submit local clinical trial data, but sufficient international clinical research information must be provided to demonstrate the medicine’s safety and efficacy. If the clinical data submitted comes from internationally recognised regulatory authorities or literature, the Drug Office will accept it. For innovative medicines or special indications, the Drug Office may also request supplementary information. Overall, Hong Kong’s registration process places greater emphasis on international data supporting medicine quality and safety.
Q465 · 香港药牌申请对药品标签和说明书有哪些具体要求？独立链接
Hong Kong requires medicine labels and package inserts to be presented bilingually in Chinese and English. They should include the medicine name, pharmaceutical product registration number (HK-XXXXX), ingredients, directions and dosage, indications, adverse reactions, storage conditions and manufacturer information, among other details. Labels must comply with the Department of Health’s format requirements to ensure that consumers can clearly understand the information. In addition, all promotional materials must not contain false or misleading statements and must comply with the relevant provisions of the Pharmacy and Poisons Ordinance.
Q466 · 在香港申请药牌时，如何处理与内地已有注册的药品数据差异？独立链接
Hong Kong pharmaceutical licence applications may use existing registration data from Mainland China, but applicants must ensure that the data meets Hong Kong regulatory requirements, including quality standards and safety assessments. As standards differ between the two jurisdictions, some data may need to be adjusted or supplemented, for example, ingredient specifications, excipients and packaging information. Applicants are advised to prepare supplementary information for the Hong Kong market and communicate promptly with the Drug Office, Department of Health, to ensure that the submission is complete and complies with local requirements.
Q467 · 香港药牌审批时间通常需要多久？独立链接
In general, the approval process for a Hong Kong pharmaceutical licence takes around 3 to 6 months, depending on the completeness and complexity of the application. If the documents are complete and meet the requirements, approval may be relatively quick; if further information is needed or an on-site inspection is conducted, the process may take longer. Compared with pharmaceutical registration in Mainland China, the Hong Kong process is simpler, but a reasonable amount of time should still be allowed. Applicants should prepare in advance and cooperate fully with the Drug Office’s review requirements.
Q468 · 跨境医药企业在香港申请药牌时需要具备哪些资格或条件？独立链接
Cross-border pharmaceutical companies applying for Hong Kong pharmaceutical licences must be legally registered in Hong Kong or overseas, have a good business record and comply with the Pharmacy and Poisons Ordinance (Cap.138). They must appoint a local representative in Hong Kong (such as an agent) to liaise with the Drug Office, Department of Health, and ensure that information is complete and updated promptly. They must also have a robust pharmaceutical Quality Management System and post-market tracking mechanism to ensure the safe distribution of medicines.
Q469 · 申请香港药牌时如何处理药品成分与内地标准不一致的情况？独立链接
If the ingredients of a medicine registered in Hong Kong differ from mainland standards, the applicant must submit detailed ingredient information and a safety assessment report to demonstrate that the formulation complies with Hong Kong standards and is safe and effective. Labelling information must be adjusted where necessary to reflect the actual ingredients. The Drug Office will assess the application based on the actual risks and scientific evidence to ensure public safety in the use of medicines. It is advisable to compare the ingredients and prepare comprehensive technical information before applying.
Q470 · 香港药牌注册后，药品的变更申报有哪些要求？独立链接
After a medicine is registered in Hong Kong, if there are significant changes to its ingredients, manufacturing process, packaging or labelling, the applicant must submit a change application to the Drug Office, Department of Health, and obtain approval before implementing the changes. The change submission must include an explanation of the changes and relevant supporting information to ensure that they do not affect the medicine’s quality or safety. Minor changes should also be recorded and documented. Failure to notify changes as required may be regarded as an offence.
Q471 · 什么是「1+」新药审批机制，其适用范围具体包括哪些类别的新药？独立链接
The “1+” new drug approval mechanism is an expedited approval pathway established by the Drug Office, Department of Health, to accelerate the introduction of innovative and promising new medicines to the local market. It primarily applies to innovative medicines, biologics and certain medicines for rare diseases being submitted for registration in Hong Kong for the first time. The mechanism focuses on existing approval data from internationally recognised drug regulatory authorities (such as the FDA and EMA), reducing duplicate review work and thereby shortening approval times. It does not apply to generic medicines or over-the-counter medicines already registered locally. The aim is to encourage innovative pharmaceutical companies to accelerate their expansion into overseas markets and enhance Hong Kong’s competitiveness as a regional pharmaceutical innovation hub.
Q472 · 「1+」新药审批机制对创新药企的跨境出海有何战略意义？独立链接
By simplifying the approval process and shortening the approval period, the “1+” new drug approval mechanism provides important support for innovative pharmaceutical companies seeking to obtain a drug licence in Hong Kong more quickly. As an international financial and healthcare hub, successful medicine registration in Hong Kong can serve as a springboard into the Greater China region and wider Asian markets, strengthening companies’ competitiveness. In addition, recognition of data from internationally recognised regulatory authorities helps reduce the cost of duplicate trials and improve the efficiency of new drug development. For innovative pharmaceutical companies, this means products can be commercialised earlier, cash flow optimised and global expansion strengthened, significantly improving the likelihood and speed of successful expansion into overseas markets.
Q473 · 「1+」新药审批机制对申请资料的具体要求有哪些？独立链接
Under the “1+” new drug approval mechanism, applicants must submit detailed information on the medicine’s quality, safety and efficacy, giving priority to data already reviewed and approved by internationally recognised regulatory authorities such as the FDA, EMA and PMDA. This includes complete clinical trial reports, pharmacology and toxicology studies, and manufacturing process and quality control documents. Applicants must also provide detailed product information and a risk management plan. The Drug Office, Department of Health emphasises the scientific rigour and transparency of the information to ensure accurate and efficient assessment. The submitted information must be structured in accordance with the Pharmacy and Poisons Ordinance (Cap. 138) and the relevant implementing rules.
Q474 · 申请「1+」新药审批机制需要满足哪些具体条件？独立链接
To qualify for the “1+” new drug approval mechanism, the following conditions must be met: first, the medicine must be an innovative new drug or a drug being submitted for registration in the Hong Kong market for the first time; second, the applicant must demonstrate that the drug has been approved by at least one internationally authoritative drug regulatory authority; third, complete clinical and quality data must be submitted in accordance with local Hong Kong regulatory requirements; and finally, the applicant must have a lawful local registration representative or agent. Only applications meeting these conditions may benefit from a shortened approval timeline, priority review and other measures to improve review efficiency.
Q475 · 「1+」新药审批机制下，审批流程与传统审批有何不同？独立链接
Under the “1+” new drug approval mechanism, the approval process is simpler and faster than the traditional process. First, after an application is submitted, the Drug Office prioritises assigning a dedicated officer to follow it up, reducing the initial review time. Second, the mechanism allows the use of approval data from internationally authoritative bodies, reducing the need for repeated testing and review. Third, the approval period is generally shortened to within 6 months, compared with 12 months or more under the traditional process. In addition, interdepartmental coordination meetings are arranged during the approval process to resolve technical issues promptly and keep the process moving smoothly. The overall aim is to improve approval efficiency and speed up the launch of innovative medicines in Hong Kong.
Q476 · 「1+」新药审批机制如何处理跨境临床试验数据的认可问题？独立链接
The “1+” mechanism places emphasis on accepting international clinical trial data. Hong Kong’s Drug Office recognises results from cross-border clinical trials reviewed by internationally recognised regulatory authorities, provided that the data meet local scientific and ethical standards in Hong Kong. Applicants must provide complete reports on the trial design, conduct and results, and demonstrate compliance with the Clinical Trials Ordinance (Cap. 623) and relevant international guidelines, such as ICH-GCP. The data must also be transparent and traceable to ensure reliability. This helps reduce the need for duplicate trials and accelerate the local registration of new medicines.
Q477 · 「1+」新药审批机制对已获国际批准药品在香港的市场准入时限有何影响？独立链接
Under the ‘1+’ approval mechanism, new medicines that have already received international approval can gain access to the Hong Kong market significantly faster. The traditional approval process can take a year or longer, whereas the ‘1+’ mechanism can reduce the approval time to within 6 months, or even less. This offers considerable strategic value to innovative pharmaceutical companies seeking to enter the Hong Kong and Greater China markets quickly. Faster access can also help secure a market advantage and strengthen competitiveness, while reducing the time and capital required and enabling commercial returns to be realised sooner.
Q478 · 「1+」新药审批机制是否适用于所有类型的创新药物？有哪些限制？独立链接
The “1+” new drug approval mechanism primarily applies to innovative medicines being registered in Hong Kong for the first time, including new chemical entities, biologics and some medicines for rare diseases. However, it does not apply to generic medicines, over-the-counter medicines or similar products already registered in the Hong Kong market. It also does not apply to medicines with significant safety concerns or without sufficient support from international certification. The mechanism is designed to focus on innovation and international recognition, ensuring that medicines approved through the expedited process have a sound basis for safety and efficacy and thereby protecting public health.
Q479 · 「1+」新药审批机制对药品上市后监管有何特别要求？独立链接
Although the “1+” mechanism accelerates the approval process, medicines must still comply strictly with Hong Kong's pharmaceutical regulations after they enter the market. Applicants must establish a comprehensive Risk Management Plan (RMP), submit periodic safety update reports (PSURs), and cooperate with the Drug Office in monitoring and investigating adverse drug reactions. In addition, for new medicines involving rare diseases or biological products, regulators may require post-market clinical studies to continue assessing safety and efficacy. Strict post-market regulation helps ensure public safety in the use of medicines while safeguarding product quality and the company's reputation.
Q480 · 「1+」新药审批机制是否支持跨境合作研发药物的注册申请？独立链接
The “1+” new drug approval mechanism supports registration applications for innovative medicines developed through cross-border collaboration. Applicants may submit clinical and registration data from partners in other countries or regions and draw on internationally recognised data to accelerate the approval process. The mechanism also encourages cross-border data sharing and regulatory coordination, simplifying the acceptance of clinical trial data from multiple countries and supporting the global development of innovative medicines. Companies must ensure that collaboration agreements clearly define data ownership and the allocation of responsibilities, and comply with Hong Kong’s regulatory requirements to safeguard the completeness and lawfulness of the application materials.